Riskpilot← Back to searchSign inGet full accessPROPHYLAXIA SIGNS AS
ASActiveOrg 995594447Daugstadvegen 445, 6392 VikebuktResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20100 employees
Revenue 2024
NOK 3,9M
+64% vs 2023
EBITDA margin
23.9%
-11% vs 2023
Equity ratio
-127.9%
Financial strength
Net profit 2024
NOK 541K
+201% vs 2023
| Revenue | NOK 3,9M | +64% |
| EBITDA | NOK 922K | -11% |
| Net profit | NOK 541K | +201% |
| Total assets | NOK 2,5M | -55% |
| Equity | NOK -3,1M | +15% |
| Employees | 0 | — |
Legal name
PROPHYLAXIA SIGNS AS
Org number
995594447
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9. juni 2010
Share capital
NOK 150 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Forske og utvikle bioteknologiske produkter innen signalsubstanser hovedsakelig til akvanæringen, selge og markedsføre disse, samt å delta i annen virksomhet med beslektet type aktivitet.
Address
Daugstadvegen 445, 6392 Vikebukt
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 1 816 | 1 596 | 2 354 | 3 859 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −220 | −1 220 | 214 | 1 034 | 922 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −220 | −1 220 | 214 | 1 034 | 922 |
| Net financials | −6 | −820 | −1 927 | −854 | −381 |
| Profit before tax | −226 | −2 040 | −1 712 | 180 | 541 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −226 | −2 040 | −1 712 | 180 | 541 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 55 | 5 106 | 2 221 | 5 416 | 2 461 |
| Equity | −116 | −2 156 | −3 869 | −3 689 | −3 148 |
| Long-term debt | 0 | 6 918 | 5 644 | 6 406 | 3 685 |
| Short-term debt | 171 | 345 | 446 | 2 698 | 1 924 |
| Total debt | 171 | 7 262 | 6 090 | 9 104 | 5 609 |
EBITDA margin
23.9%
This company
15.8%
Market median
+51% vs market
20202024
Equity ratio
-127.9%
This company
38.2%
Market median
-435% vs market
20202024
Return on equity
54079600.0%
This company
18.4%
Market median
+293910770% vs market
20202024
Net profit margin
14.0%
This company
8.1%
Market median
+73% vs market
20202024
Asset turnover
1.57×
This company
1.12×
Market median
+40% vs market
20202024
Debt / equity
1.78×
This company
0.62×
Market median
-187% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
IG Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2022 | |
| Former (1) | ||
| Board of Directors | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 51% | 51% | 2022 | |
Signs Sas | Company | 49% | 49% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PROPHYLAXIA SIGNS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ivar Gulla | Chief Executive Officer | 0 companies |
| Patrick Christian Pageat | Board of Directors | 0 companies |
| Bjørn-Vegard Løvik | Chairman | 0 companies |